Egenesis

Cambridge, MA · Founded 2015 · Privately Held (backing)

Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs. Egenesis is based in Cambridge, MA and was founded in 2015. Its last known valuation is $330 million. It has raised $454 million across 5 recorded rounds; the latest was a $25.4 million debt round in Feb 2024.

Last price · $/share
—
Implied valuation
$330.0M
Total raised
$454.0M
Last round
Debt
Feb 2024
No prints on record

No secondary trades in Egenesis shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Egenesis with a free account
  • ·The complete investor list: 37 names
  • ·Watch Egenesis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Egenesis prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Egenesis stock.